{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T06:11:55Z","timestamp":1791439915175,"version":"4.3.3"},"reference-count":22,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000849","name":"National Centre for the Replacement, Refinement and Reduction of Animals in Research","doi-asserted-by":"publisher","award":["NC\/NAM0019\/1"],"award-info":[{"award-number":["NC\/NAM0019\/1"]}],"id":[{"id":"10.13039\/501100000849","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["UKRI076"],"award-info":[{"award-number":["UKRI076"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Leicester Impact Acceleration Account","award":["NA"],"award-info":[{"award-number":["NA"]}]}],"content-domain":{"domain":["www.plosbiology.org"],"crossmark-restriction":false},"short-container-title":["PLoS Biol"],"abstract":"<jats:p>The experimental use of antibodies that have not been validated for context-specific use frequently misdirects biomedical research. Experimental results that derive from the use of inadequately validated antibodies are estimated to waste over $1 billion annually in the United States alone and to consume millions of animal and human biological samples in experiments whose conclusions may be unreliable. Community validation frameworks, reporting standards, and independent characterisation initiatives have made important progress, and multi-stakeholder coordination efforts are emerging. However, the research community lacks a formally developed, consensus-based action plan that specifies what each stakeholder group should do, by when, and with what priority. We conducted a modified Delphi study with international experts representing academic researchers, scientific publishers, research funders, antibody manufacturers, and institutional research leaders to develop actionable recommendations for improving antibody validation, selection, and reporting practices. Thirty-two participants rated 33 proposed actions on effectiveness and feasibility using 9-point scales, with consensus assessed using the RAND\/UCLA Appropriateness Method. Over two rounds, the panel achieved consensus on 15 items as both effective and feasible for implementation by 2030. These spanned institutional actions (training in antibody validation, integration into research integrity frameworks, support for local expertise networks), funder actions (dedicated validation budgets, grant application requirements, endorsement of community reporting standards), publisher actions (complete antibody reporting packages, clear validation standards), manufacturer actions (assignment of unique identifiers at source), and cross-stakeholder coordination (a shared roadmap for improvement). An additional 15 items were rated as effective but with uncertain feasibility, reflecting a consistent pattern in which the panel agreed on the value of proposed interventions but expressed reservations about realistic implementation timelines. One item was rejected by the panel with concerns around effectiveness and feasibility. Participants described four interconnected barriers to progress: diffuse ownership of the problem across stakeholders; market dynamics that inadequately reward antibody quality; difficulty justifying investment when returns are distributed across the research system; and coordination challenges among actors with different incentive structures. These barriers are addressable through coordinated action, and the findings complement existing technical and data-sharing initiatives by providing the structured, expert-informed policy framework to help translate awareness of the problem into concrete practice and policy changes.<\/jats:p>","DOI":"10.1371\/journal.pbio.3003981","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:23:20Z","timestamp":1791307400000},"page":"e3003981","update-policy":"https:\/\/doi.org\/10.1371\/journal.pbio.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Actionable solutions to address antibody validation failures"],"prefix":"10.1371","volume":"24","author":[{"given":"Katherine","family":"Blades","sequence":"first","affiliation":[{"name":"University of Leicester","place":["Leicester, United Kingdom"],"department":["School of Medical Sciences, College of Life Sciences"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Biddle","sequence":"additional","affiliation":[{"name":"University of Leicester","place":["Leicester, United Kingdom"],"department":["School of Medical Sciences, College of Life Sciences"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Froud","sequence":"additional","affiliation":[{"name":"School of Health Sciences, Kristiania University of Applied Sciences","place":["Oslo, Norway"]},{"name":"Warwick Medical School, University of Warwick","place":["Coventry, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8748-9897","authenticated-orcid":true,"given":"Eva M.","family":"Krockow","sequence":"additional","affiliation":[{"name":"University of Leicester","place":["Leicester, United Kingdom"],"department":["School of Psychology and Vision Sciences, College of Life Sciences"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9739-9593","authenticated-orcid":true,"given":"Harvinder","family":"Virk","sequence":"additional","affiliation":[{"name":"University of Leicester","place":["Leicester, United Kingdom"],"department":["School of Medical Sciences, College of Life Sciences"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"key":"pbio.3003981.ref001","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.91645.2","article-title":"Scaling of an antibody validation procedure enables quantification of antibody performance in major research applications","volume":"12","author":"R Ayoubi","year":"2023","journal-title":"Elife"},{"issue":"5","key":"pbio.3003981.ref002","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1182\/blood-2005-10-4066","article-title":"Anti-Epo receptor antibodies do not predict Epo receptor expression","volume":"107","author":"S Elliott","year":"2006","journal-title":"Blood"},{"issue":"10","key":"pbio.3003981.ref003","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1074\/mcp.R800013-MCP200","article-title":"A genecentric Human Protein Atlas for expression profiles based on antibodies","volume":"7","author":"L Berglund","year":"2008","journal-title":"Mol Cell Proteomics"},{"issue":"5","key":"pbio.3003981.ref004","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/j.1365-2559.2011.04034.x","article-title":"Human epidermal growth factor receptor 2 (HER2) immunoreactivity: specificity of three pharmacodiagnostic antibodies","volume":"59","author":"A-S Schrohl","year":"2011","journal-title":"Histopathology"},{"issue":"3","key":"pbio.3003981.ref005","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2144\/000114074","article-title":"Commercial Cdk1 antibodies recognize the centrosomal protein Cep152","volume":"55","author":"G Lukinavi\u010dius","year":"2013","journal-title":"Biotechniques"},{"issue":"7552","key":"pbio.3003981.ref006","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/521274a","article-title":"Reproducibility crisis: Blame it on the antibodies","volume":"521","author":"M Baker","year":"2015","journal-title":"Nature"},{"key":"pbio.3003981.ref007","doi-asserted-by":"crossref","first-page":"15840","DOI":"10.1038\/ncomms15840","article-title":"Insufficient antibody validation challenges oestrogen receptor beta research","volume":"8","author":"S Andersson","year":"2017","journal-title":"Nat Commun"},{"key":"pbio.3003981.ref008","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.48363","article-title":"Implementation of an antibody characterization procedure and application to the major ALS\/FTD disease gene C9ORF72","volume":"8","author":"C Laflamme","year":"2019","journal-title":"Elife"},{"issue":"1","key":"pbio.3003981.ref009","doi-asserted-by":"crossref","first-page":"18500","DOI":"10.1038\/s41598-019-55133-7","article-title":"Validation of antibodies for the specific detection of human TRPA1","volume":"9","author":"HS Virk","year":"2019","journal-title":"Sci Rep"},{"issue":"8037","key":"pbio.3003981.ref010","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/d41586-024-03590-0","article-title":"The antibodies don\u2019t work! The race to rid labs of molecules that ruin experiments","volume":"635","author":"D Kwon","year":"2024","journal-title":"Nature"},{"issue":"6","key":"pbio.3003981.ref011","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1002165","article-title":"The Economics of Reproducibility in Preclinical Research","volume":"13","author":"LP Freedman","year":"2015","journal-title":"PLoS Biol"},{"key":"pbio.3003981.ref012","article-title":"Antibody characterization is critical to enhance reproducibility in biomedical research","volume":"13","author":"RA Kahn","year":"2024","journal-title":"Elife"},{"issue":"7974","key":"pbio.3003981.ref013","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/d41586-023-02566-w","article-title":"Heed a decade of calls for antibody validation","volume":"620","author":"RA Kahn","year":"2023","journal-title":"Nature"},{"issue":"10","key":"pbio.3003981.ref014","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3003984","article-title":"Inadequate antibody validation places substantial numbers of animal and human tissue samples at risk of waste","volume":"24","author":"M Biddle","year":"2026","journal-title":"PLoS Biol"},{"issue":"10","key":"pbio.3003981.ref015","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/nmeth.3995","article-title":"A proposal for validation of antibodies","volume":"13","author":"M Uhlen","year":"2016","journal-title":"Nat Methods"},{"issue":"17","key":"pbio.3003981.ref016","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2103238118","article-title":"The MDAR (Materials Design Analysis Reporting) Framework for transparent reporting in the life sciences","volume":"118","author":"M Macleod","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"pbio.3003981.ref017","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.neuron.2016.04.030","article-title":"RRIDs: a simple step toward improving reproducibility through rigor and transparency of experimental methods","volume":"90","author":"AE Bandrowski","year":"2016","journal-title":"Neuron"},{"issue":"1","key":"pbio.3003981.ref018","doi-asserted-by":"crossref","first-page":"2323706","DOI":"10.1080\/19420862.2024.2323706","article-title":"Improving the integrity and reproducibility of research that uses antibodies: a technical, data sharing, behavioral and policy challenge","volume":"16","author":"M Biddle","year":"2024","journal-title":"MAbs"},{"key":"pbio.3003981.ref019","volume-title":"The RAND\/UCLA appropriateness method user\u2019s manual","author":"K Fitch","year":"2001"},{"issue":"5","key":"pbio.3003981.ref020","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S0016-3287(69)80025-X","article-title":"An experimental study of group opinion","volume":"1","author":"N Dalkey","year":"1969","journal-title":"Futures"},{"issue":"9","key":"pbio.3003981.ref021","doi-asserted-by":"crossref","first-page":"979","DOI":"10.2105\/AJPH.74.9.979","article-title":"Consensus methods: characteristics and guidelines for use","volume":"74","author":"A Fink","year":"1984","journal-title":"Am J Public Health"},{"key":"pbio.3003981.ref022","unstructured":"Virk H, Eyre R, Holmes A, Biddle M, Krockow E. Defining the role of antibodies in improving research reproducibility: NC3Rs and Only Good Antibodies community meeting report. London: NC3Rs; 2024 [cited 2026 Feb 8]. Available from: https:\/\/nc3rs.org.uk\/sites\/default\/files\/2024-07\/NC3Rs-OGA%20Meeting%20report%20%E2%80%93%20Defining%20the%20role%20of%20antibodies%20in%20improving%20research%20reproducibility.pdf"}],"container-title":["PLOS Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pbio.3003981","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:23:26Z","timestamp":1791307406000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pbio.3003981"}},"subtitle":[],"editor":[{"given":"Eunjoon","family":"Kim","sequence":"first","affiliation":[{"name":"Institute for Basic Science","place":["KOREA, REPUBLIC OF"]}],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":22,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10,6]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pbio.3003981","relation":{},"ISSN":["1545-7885"],"issn-type":[{"value":"1545-7885","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,6]]}}}